Tuesday, December 12, 2017

© Reuters.  BioDelivery Sciences settles Bunavail patent dispute with Teva© Reuters. BioDelivery Sciences settles Bunavail patent dispute with Teva

  • BioDelivery Sciences (NASDAQ:BDSI) settles its patent infringement litigation with Teva Pharmaceutical Industries’ (NYSE:TEVA) U.S. unit related to BUNAVAIL (buprenorphine and naloxone). Teva had filed a marketing application seeking FDA approval for a generic version of the product.
  • Under the terms of the settlement, BioDelivery grants Teva a non-exclusive license to sell a generic equivalent beginning July 23, 2028 or earlier under certain circumstances.

Original article

sponsoredArticle = ‘div-gpt-ad-1466339494851-0’;

Banner Content